MedPath

NIHON MEDI-PHYSICS CO., LTD.

NIHON MEDI-PHYSICS CO., LTD. logo
🇯🇵Japan
Ownership
Joint Venture
Established
1973-01-01
Employees
5K
Market Cap
-
Website
http://www.nmp.co.jp

Clinical Trials

14

Active:0
Completed:10

Trial Phases

3 Phases

Phase 1:4
Phase 2:6
Phase 3:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials

Phase 2
6 (42.9%)
Phase 1
4 (28.6%)
Phase 3
4 (28.6%)

Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer

Phase 1
Recruiting
Conditions
Pancreatic Cancer
Interventions
First Posted Date
2023-11-13
Last Posted Date
2025-06-11
Lead Sponsor
Nihon Medi-Physics Co., Ltd.
Target Recruit Count
10
Registration Number
NCT06129422
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

BAMF Health, Grand Rapids, Michigan, United States

🇺🇸

Fred Hutchinson Cancer Center, Seattle, Washington, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.